Edition:
United States

BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

324.10ILa
27 Apr 2017
Change (% chg)

-0.20 (-0.06%)
Prev Close
324.30
Open
323.70
Day's High
338.00
Day's Low
321.20
Volume
123,966
Avg. Vol
153,146
52-wk High
500.00
52-wk Low
287.50

BLRX.TA

Chart for BLRX.TA

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)
No analyst recommendations are available for BLRX.TA.

Overall

Beta: -0.09
Market Cap(Mil.): ₪310.48
Shares Outstanding(Mil.): 95.62
Dividend: --
Yield (%): --

Financials

  BLRX.TA Industry Sector
P/E (TTM): -- 58.41 30.30
EPS (TTM): -1.02 -- --
ROI: -37.97 0.45 13.24
ROE: -38.34 6.31 14.40

BRIEF-BVF Inc reports 18.3 pct passive stake in Bioline RX Ltd

* BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017 Source text:(http://bit.ly/2p0kRot) Further company coverage:

Apr 10 2017

BRIEF-BioLineRx prices $25 mln underwritten public offering

* BioLine rx ltd - priced underwritten public offering of about 29.4 million ADSs at public offering price of $0.85 per ads Source text for Eikon: Further company coverage:

Mar 31 2017

BRIEF-BioLine RX announces underwritten public offering of its american depositary shares

* BioLine RX announces underwritten public offering of its american depositary shares

Mar 30 2017

BRIEF-BiolineRX announces acquisition of Agalimmune Ltd

* Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline

Mar 23 2017

BRIEF-Biolinerx announces initiation of Immuno-oncology Phase 2 study

* Biolinerx announces initiation of Immuno-oncology Phase 2 study to investigate combination of BL-8040 and keytruda for pancreatic cancer Source text for Eikon: Further company coverage:

Jan 17 2017

BRIEF-Biolinerx reports Q3 financial results

* Bioline RX Ltd - operating loss for three months ended September 30, 2016 amounted to $4.5 million versus operating loss of $3.6 million

Nov 22 2016

BRIEF-BioLine RX in-licenses novel anti-inflammatory treatment for dry eye syndrome under strategic collaboration with major global pharmaceutical company

* BioLine RX Ltd - in addition to des, biolinerx intends to explore potential use of bl-1230 in systemic inflammatory conditions

Nov 21 2016

BRIEF-Bioline RX discloses positive correlative data from phase 2A AML study

* Biolinerx discloses positive correlative data from phase 2a aml study and mechanism-of-action data for bl-8040 oncology platform at ash 2016

Nov 03 2016

More From Around the Web

Earnings vs. Estimates